FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Extreme Makeover: Wall Street Edition
- Lightning Round: Knight Capital, Potash, CPFL Energia and More
- Lightning Round OT: Enersis, Activision Blizzard and More
- Warren Buffett’s Favorite Coal Stock?
- The FDIC’s Newest Darling?
- Cramer: Praise Bernanke, Buy These Stocks
- Cramer: Retail Investors Returning to Market?
- Mad Mail: Does the iPhone Still Have a Chance in China?
- Lightning Round: CVS Caremark, Devon Energy, Tyson Foods and More
- Lightning Round OT: Ford, NewAlliance Bancshares and More
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
All the benefits of liposuction without any of the scars.
That’s what Medicis Pharmaceuticals’ [MRX
Loading...
()
] new acquisition LipoSonix Technology promises. It’s a process that uses focused ultrasound to break up fat beneath the skin so the body can naturally clear the excess weight away. No surgery at all.
Jonah Shacknai, chairman and CEO of Medicis, told Cramer Friday that a 45-minute minute treatment has been proved to reduce the waistline by “several inches in many cases.”
“Our reasoning is there’s almost no one who wouldn’t go for a treatment like this,” Shacknai said.
Analysts, though, don’t seem to share the CEO’s enthusiasm. Many think the LipoSonix buy was a bad one, and there’s doubt the technology will make it past the Food and Drug Administration.
Shacknai attributes the sentiment to this tough market, saying, “It’s easier to be negative than positive” right now. LipoSonix is already selling well in Europe and Asia, he said, and the company sees “a very clear path to FDA approval in the United States.”
“I’m not saying whether to buy or sell the stock,” Cramer told viewers. “I am saying that the criticism that he’s getting here is very small-minded. You do the work. You make the decision. But I think this acquisition made a lot of sense to me.”
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes